Hospital Auxilio Mutuo in Puerto Rico Advances its Lab Testing for Transplant Patients with the Atellica Solution

  • The sole transplant center in Puerto Rico will be able to expand
    its testing menu to grow its services and to help improve outcomes for
    its transplant patients.

MALVERN, Pa.–(BUSINESS WIRE)–Siemens Healthineers announced today that Hospital Auxilio Mutuo in
Puerto Rico has become the first hospital on the island and the first
transplant center in the world to advance its laboratory testing with
the Atellica® Solution.1 The immunoassay and
clinical chemistry analyzers from Siemens Healthineers offer
laboratories state-of-the-art testing capabilities and a comprehensive
test menu to help improve patient outcomes.

When preparing a patient for a transplant, a variety of testing needs to
be conducted to help determine if a patient is healthy enough for
surgery. Early identification of antibodies that may cause a possible
graft rejection and also the ability to detect a patient’s viral load
are important testing that needs to occur in the pre- and post-
transplant phases to monitor the possibility of infection. In the
post-transplant period, among the most important test results for
clinicians are donor-specific antibodies which could indicate a donor is
rejecting the transplant. This testing needs to deliver results quickly
and efficiently.

“We are in a new era in the laboratory,” said Francheska Rivera,
Laboratory Supervisor at Hospital Auxilio Mutuo. “Our main goal is to
improve the laboratory with state-of-the-art instrumentation to ensure
the highest standards as much as possible. The focus and vision is
quality patient care with the best resources available in the market,
and best-in-class technology and service that meets our goals. The
Atellica Solution allows, among other things, us to consolidate four
instruments into one by integrating the immunoassay and clinical
chemistry analyzers, to improve efficiency, and to maximize our staff.”

Hospital Auxilio Mutuo in Puerto Rico runs more than 70,000 tests on a
monthly basis. The Atellica Solution will enable the laboratory to
consolidate several instruments for improved efficiency in the lab,
while growing its testing capacity and menu to better serve its patients.

“Specialty facilities across North America are entrusting the Atellica
Solution from Siemens Healthineers with the testing needs of their most
fragile patients,” said Andy Olen, Senior Vice President, Diagnostics,
North America, Siemens Healthineers. “With its comprehensive menu and
unique features and benefits for quality control, the Atellica Solution
is proving to be an offering to help laboratories across the country to
improve patient outcomes, optimize their workflow, grow their testing
menu, or expand their capabilities.”

For further information on the Atellica Solution, please visit www.siemens-healthineers.us/atellicasolution

1 Product availability varies by country.

Siemens Healthineers enables healthcare providers worldwide to
increase value by empowering them on their journey towards expanding
precision medicine, transforming care delivery, improving patient
experience and digitalizing healthcare. A leader in medical technology,
Siemens Healthineers is constantly innovating its portfolio of products
and services in its core areas of diagnostic and therapeutic imaging and
in laboratory diagnostics and molecular medicine. Siemens Healthineers
is also actively developing its digital health services and enterprise
services. In fiscal 2018, which ended on September 30, 2018, Siemens
Healthineers generated revenue of €13.4 billion and adjusted profit of
€2.3 billion and has about 50,000 employees worldwide. Further
information is available at www.siemens-healthineers.com.

Contacts

For journalists
Kimberly Nissen, Siemens Healthineers
Phone:
+1 610 448-6355; Email: [email protected]

error: Content is protected !!